TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36854071
Drug: Dinutuximab beta
Normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dinutuximab beta (DB) plus subcutaneous interleukin-2 (scIL2) after haplo-SCT
Study: 36854570
Drug: Bispecific antibody
Normalized name: Bispecific antibody 520c9x22
DrugBank: MDX-210 (DB17250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific antibody (bsAb)-KN046
Study: 36854583
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy for 12 weeks
Study: 36854604
Drug: Afatinib combined
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib combined with GEMOX chemotherapy (gemcitabine and oxaliplatin)
Study: 36855089
Drug: Morphine-based analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-based analgesia
Study: 36855099
Drug: Tafolecimab 150
Normalized name: Tafolecimab
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafolecimab 150 mg Q2W
Study: 36855099
Drug: Tafolecimab 450
Normalized name: Tafolecimab
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafolecimab 450 mg Q4W
Study: 36855099
Drug: Tafolecimab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafolecimab (both doses)
Study: 36855109
Drug: 300,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300,000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily (n = 151)
Study: 36855160
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous ketamine infusions
Study: 36855169
Drug: Wangbi granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wangbi granule 12.0 g, three times a day for 12 weeks
Study: 36855169
Drug: Wangbi placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wangbi placebo 12.0 g, three times a day for 12 weeks
Study: 36855177
Drug: estradiol treatment
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol treatment for 3 weeks
Study: 36855177
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo treatment for 3 weeks
Study: 36855334
Drug: Standard-of-Care Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-Care Treatment
Study: 36856104
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy selected designed program (Control)
Study: 36856122
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of fermented milk
Study: 36856280
Drug: Doubled semitendinosus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubled semitendinosus and gracilis tendon (ST/G) graft
Study: 36856456
Drug: Novel Dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel Dietary Supplement
Study: 36856614
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg once daily
Study: 36856617
Drug: Neoadjuvant-adjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant-adjuvant pembrolizumab (3 doses before surgery and 15 doses after surgery)
Study: 36856617
Drug: Adjuvant-only pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant-only pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses)
Study: 36856701
Drug: Memantine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10-20 mg/day)
Study: 36856733
Drug: Temozolomide (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (first-line chemotherapy)
Study: 36856733
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (second-line treatment)
Study: 36856733
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors and everolimus
Study: 36856978
Drug: Topical cyclosporine-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis) instilled once daily to both eyes from 3-5 weeks pre-HSCT to 12 months post-HSCT
Study: 36856978
Drug: Topical cyclosporine-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis)
Study: 36857053
Drug: Intensive BP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive BP treatment (SBP target <120 mm Hg)
Study: 36857058
Drug: Implant-based reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-based reconstruction (IBR)
Study: 36857339
Drug: RELiZORB enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: RELiZORB enzyme cartridge used daily with enteral nutrition (EN) for 90 days
Study: 36857393
Drug: ATG 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG 6.0 mg/kg
Study: 36857596
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Aspirin
Study: 36858257
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at 0.03 mcg/kg/min
Study: 36858257
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at 0.02 mcg/kg/min
Study: 36858257
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion at 0.01 mcg/kg/min
Study: 36858257
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (all doses)
Study: 36858721
Drug: Lenvatinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days)
Study: 36858721
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off)
Study: 36858722
Drug: OEPA (vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OEPA (vincristine 1·5 mg/m², etoposide, prednisone, and doxorubicin) without radiotherapy
Study: 36859316
Drug: Nalmefene 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 0.25 µg/kg
Study: 36859467
Drug: Oral triheptanoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triheptanoin at a dose of 1 g/Kg/day, providing near 35% of total caloric intake.
Study: 36859467
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose of triheptanoin at 45% of daily caloric intake for each age group.
Study: 36859467
Drug: Triheptanoin treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triheptanoin treatment.
Study: 36860319
Drug: Cetuximab-based treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab-based treatment regimen
Study: 36861013
Drug: Arbaclofen extended-release
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arbaclofen extended-release 80 mg/day
Study: 36861013
Drug: Arbaclofen extended-release
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arbaclofen extended-release
Study: 36861188
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg (single dose) administered using two pediatric formulations: 0.1 mg sprinkle capsule (age <28 days) and 0.4 mg/ml solution (age 28 days to <18 years); dose range 1.08-2.19 mg/mL.
Study: 36861346
Drug: Recombinant von
Normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant von Willebrand factor (rVWF) therapy, administered as long-term routine twice weekly prophylaxis.
Study: 36861346
Drug: Recombinant von
Normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant von Willebrand factor (rVWF) therapy.
Study: 36861433
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg and Reboxetine 6 mg (oxy-reb)
Study: 36861447
Drug: Platinum-free chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-free chemotherapy
Study: 36861976
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg by mouth twice daily on day 1 followed by 200 mg by mouth twice daily on days 2 to 5)
Study: 36861976
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo with the same schedule)
Study: 36863287
Drug: Point-of-care HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care HCV RNA testing, linkage to nursing care, and peer-supported engagement/delivery of treatment
Study: 36863386
Drug: 1-2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 g of ferric carboxymaltose intravenously
Study: 36863386
Drug: Three tablets
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three tablets of 200 mg of oral ferrous fumarate daily
Study: 36863390
Drug: Swallowed topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowed topical fluticasone propionate 880 μg twice per day after 6FED non-responders
Study: 36863410
Drug: Nociception Level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nociception Level (NOL) monitoring with sevoflurane and alfentanil (10 µg/kg)
Study: 36863860
Drug: Therapists' first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapists' first impression of treatment motivation
Study: 36864377
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health technology-based follow-up programme with monthly individualized digital conversations with a PT and activity tracker; additional digital follow-up from a nutritional specialist for those at nutritional risk.
Study: 36864622
Drug: RO5459072 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5459072 (100 mg twice daily; 200 mg per day)
Study: 36864699
Drug: Two consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two consecutive antagonist cycles (control)
Study: 36864705
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with a1-glucosidase alfa
Study: 36864830
Drug: Plasma L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma L and Z
Study: 36864830
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of MPOV with plasma L and Z
Study: 37997800
Drug: ACBMNCs infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACBMNCs infusion
Study: 36865179
Drug: Therapists' care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapists' care of mental health clients, including their wellbeing and experiences in treatment.
Study: 37774646
Drug: Intensive systolic
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systolic blood pressure treatment to goal < 120 mm Hg
Study: 36865252
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment to goal < 140 mm Hg
Study: 36865545
Drug: NK cell-based
Normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell-based adoptive immunotherapy from HLA-haploidentical donors
Study: 36865667
Drug: 2.5% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% diclofenac long duration sonophoresis (LDS) daily for 4 weeks
Study: 36865870
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with topical glutathione
Study: 36866658
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (simultaneous use of SCS that does and does not produce tingling sensation)
Study: 36866658
Drug: Monotherapy (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (only SCS therapy producing tingling sensation)
Study: 36866838
Drug: Isatuximab 10
Normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab 10 mg/kg once weekly for 4 weeks followed by every 2 weeks
Study: 36866838
Drug: Isatuximab 10
Normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab 10 mg/kg plus cemiplimab 250 mg every 2 weeks
Study: 36866838
Drug: Isatuximab 10
Normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab 10 mg/kg plus cemiplimab 250 mg every 4 weeks
Study: 36867504
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg apixaban
Study: 36868179
Drug: PK-guided pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK-guided pembrolizumab administration
Study: 36868179
Drug: History-controlled cohort
Normalized name: histolyn CYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: History-controlled cohort (pembrolizumab 200 mg 3-weekly for more than four cycles)
Study: 36868252
Drug: Nivolumab induction
Normalized name: nivolumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab induction treatment (240 mg every 2 weeks for 4 doses)
Study: 36868252
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab boost (1 mg/kg plus 3 mg/kg every 3 weeks)
Study: 36868252
Drug: Nivolumab maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab maintenance treatment
Study: 36868252
Drug: Nivolumab induction
Normalized name: nivolumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab induction treatment
Study: 36868261
Drug: Garadacimab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garadacimab (400 mg loading dose followed by 200 mg monthly)
Study: 36868591
Drug: Intensive cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cancer treatment and follow-up regimens
Study: 36868591
Drug: Treatment burden
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment burden
Study: 36868593
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) administered at different doses and administration intervals during laparoscopic cholecystectomy (LC)
Study: 36868877
Drug: SCB-2019 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 (2 doses, administered intramuscularly 21 days apart)
Study: 36868877
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 doses, administered intramuscularly 21 days apart)
Study: 36868914
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment with the BTK inhibitor acalabrutinib and the BCL-2 inhibitor venetoclax
Study: 36868990
Drug: ABCB5 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABCB5 treatment (3 intravenous infusions of 2 × 10)
Study: 36868990
Drug: ABCB5 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABCB5 treatment
Study: 36869251
Drug: Continued combination
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued combination therapy (Abatacept + Methotrexate)
Study: 36869356
Drug: filgotinib monotherapy
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: filgotinib monotherapy
Study: 36869356
Drug: tocilizumab monotherapy
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tocilizumab monotherapy
Study: 36869387
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of Voriconazole (4 mg/kg)
Study: 36869387
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of Voriconazole (6 mg/kg)
Study: 36869387
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of Voriconazole (Vfend®) (4 mg/kg)
Study: 36869387
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of Voriconazole (Vfend®) (6 mg/kg)
Study: 36869392
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus music therapy (MT) during hospitalization and/or during a 6-month period post-discharge
Study: 36869392
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus music therapy (MT)
Study: 38040277
Drug: Oral cinacalcet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cinacalcet
Study: 36869793
Drug: Off-Treatment
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-Treatment
Study: 36869793
Drug: On-Treatment (systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-Treatment (systemic treatment)
Study: 36870070
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (hydrocortisone, vitamin C, and thiamine)
Study: 36870093
Drug: Ganaxolone (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaxolone (maximum daily dose of 63 mg/kg/day if ≤28 kg or 1800 mg/day if >28 kg)
Study: 36870358
Drug: Hydroxyurea starting
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea starting at 20 mg/kg once daily, escalated every 8 weeks by 5 mg/kg per day to maximum tolerated dose.
Study: 36870360
Drug: Neoadjuvant sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant sintilimab monotherapy (200 mg by intravenous infusion every 21 days)
Study: 36870360
Drug: Neoadjuvant sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant sintilimab monotherapy
Study: 36870409
Drug: ZB-06 vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZB-06 vaginal film containing HC4-N, used as a single dose before intercourse
Study: 36870478
Drug: Boston Bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boston Bowel Preparation Scale (BBPS)
Study: 36870890
Drug: 1 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mcg/kg intranasal dexmedetomidine
Study: 36870890
Drug: 2 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mcg/kg intranasal dexmedetomidine
Study: 36870890
Drug: 3 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mcg/kg intranasal dexmedetomidine
Study: 36870890
Drug: 4 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mcg/kg intranasal dexmedetomidine
Study: 36870941
Drug: Paclitaxel NIPEC
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel NIPEC with systemic paclitaxel and 5-fluorouracil, administered on days 1 and 8, repeated every three weeks for 4 cycles.
Study: 36871042
Drug: AZD2811 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2811 (500 mg; Day 1; 21-day cycle with G-CSF on Day 8)
Study: 36871042
Drug: AZD2811 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2811 (various doses from 15 to 600 mg)
Study: 36871042
Drug: AZD2811 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2811 (various doses)
Study: 36871101
Drug: Pfizer-BioNTech Covid-19
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer-BioNTech Covid-19 vaccine (2 doses, 21 days apart)
Study: 36871215
Drug: Eliminating copayments
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eliminating copayments for high-value preventive medications (waived 30% copayment on 15 medication classes)
Study: 36871215
Drug: Usual copayment
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual copayment (30% copayment on medications)
Study: 36871246
Drug: Yuhan rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Yuhan rivaroxaban tablet
Study: 36871246
Drug: Xarelto tablet
Normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xarelto tablet
Study: 36871424
Drug: Pembrolizumab in
Normalized name: pembrolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab in combination with nab-paclitaxel (nP) and epirubicin/cyclophosphamide
Study: 36871476
Drug: Shenlingcao oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenlingcao oral liquid (SOL) combined with conventional chemotherapy
Study: 36871487
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab with chemotherapy (2 cycles)
Study: 36871487
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (4 cycles)
Study: 36872181
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg once daily (QD)
Study: 36872181
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg QD
Study: 36872337
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus apatinib and chemotherapy
Study: 36872457
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with two cycles of 3-weekly docetaxel 75 mg/m² and concurrent chemoradiotherapy (CCRT)
Study: 36873770
Drug: Clopidogrel monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel monotherapy after 1-month DAPT
Study: 36873770
Drug: 12-month DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month DAPT with aspirin and clopidogrel